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ABSTRACT Cryptococcus neoformans can cause fatal meningoencephalitis in pa-
tients with AIDS or other immunocompromising conditions. Current antifungals are
suboptimal to treat this disease; therefore, novel targets and new therapies are
needed. Previously, we have shown that chitosan is a critical component of the
cryptococcal cell wall and is required for survival in the mammalian host and that
chitosan deﬁciency results in rapid clearance from the mammalian host. We had also
identiﬁed several speciﬁc proteins that were required for chitosan biosynthesis, and
we hypothesize that screening for compounds that inhibit chitosan biosynthesis
would identify additional genes/proteins that inﬂuence chitosan biosynthesis. To
identify these compounds, we developed a robust and novel cell-based ﬂow cytom-
etry screening method to identify small-molecule inhibitors of chitosan production.
We screened the ICCB Known Bioactives library and identiﬁed 8 compounds that re-
duced chitosan in C. neoformans. We used ﬂow cytometry-based counterscreens and
conﬁrmatory screens, followed by a biochemical secondary screen to reﬁne our pri-
mary screening hits to 2 conﬁrmed hits. One of the conﬁrmed hits that reduced chi-
tosan content was the aminoalkylindole BML-190, a known inverse agonist of mam-
malian cannabinoid receptors. We demonstrated that BML-190 likely targets the C.
neoformans G-protein-coupled receptor Gpr4 and, via the cyclic AMP (cAMP)/protein
kinase A (PKA) signaling pathway, contributes to an intracellular accumulation of
cAMP that results in decreased chitosan. Our discovery suggests that this approach
could be used to identify additional compounds and pathways that reduce chitosan
biosynthesis and could lead to potential novel therapeutics against C. neoformans.
IMPORTANCE Cryptococcus neoformans is a fungal pathogen that kills 200,000
people every year. The cell wall is an essential organelle that protects fungi from the
environment. Chitosan, the deacetylated form of chitin, has been shown to be an
essential component of the cryptococcal cell wall during infection of a mammalian
host. In this study, we screened a set of 480 compounds, which are known to have
deﬁned biological activities, for activity that reduced chitosan production in C. neo-
formans. Two of these compounds were conﬁrmed using an alternative method of
measuring chitosan, and one of these was demonstrated to impact the cAMP signal
transduction pathway. This work demonstrates that the cAMP pathway regulates chi-
tosan biosynthesis in C. neoformans and validates that this screening approach could
be used to ﬁnd potential antifungal agents.
KEYWORDS Cryptococcus neoformans, cAMP, chitosan, drug screening, ﬂow
cytometry
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Despite the current antifungal therapies, up to 19% of AIDS-related deaths(200,000) occur globally due to cryptococcal meningitis (1–3). Several factors
contribute to this high mortality rate, including (i) toxicities from current therapies such
that many patients cannot tolerate the regimen (2, 3), (ii) the relative expense and
difﬁculty of administering some of the formulations, and (iii) the long duration of the
regimen reducing patient compliance. Although the implementation of antiretroviral
therapy (ART) has been profound in its success in reducing AIDS-related deaths (1), to
avoid immune reconstitution inﬂammatory syndrome (IRIS) that is linked to ART, ART
must be delayed until successful antifungal therapy can be applied (4, 5). With the
suboptimal efﬁcacy of current antifungal therapies, it can be challenging to avoid the
effects of IRIS. Furthermore, antimicrobial drug resistance is an identiﬁed concern when
using the current antifungal therapies against cryptococcosis (6, 7). Overall, these
concerns create the urgency for the discovery of novel targets for the development of
effective drugs against the primary etiology of AIDS-related cryptococcal meningitis,
Cryptococcus neoformans.
Chitosan is a key component of the C. neoformans cell wall and is essential for fungal
survival in the mammalian host (8, 9). The precursor to chitosan in C. neoformans is
chitin. Chitin is synthesized by one or more of the integral membrane proteins, chitin
synthases (Chs), some of which require an accessory protein (Csr), from cytoplasmic
stores of UDP N-acetylglucosamine and is then deacetylated by chitin deacetylases
(Cda) to produce chitosan. Although most fungi have genes encoding putative chitin
deacetylases, chitosan has been shown to be present in vegetatively growing cells of
a small subset of fungi, and chitosan biosynthesis has been studied for only a few
species. Chitin is made up of beta-(1,4)-linked N-acetylglucosamine (GlcNAc) mono-
mers, and when greater than 50% of these monomers are deacetylated by chitin
deacetylases to glucosamine (GlcN [8, 9]), the polymer becomes chitosan. Cryptococcus
has eight chitin synthase genes, and only one of them (CHS3) affects chitosan produc-
tion (10). Deletion of the CSR2 gene, which encodes the accessory protein suggested to
be associated with Chs3, also prevents chitosan production. The chitin produced by
Chs3/Csr2 is subsequently deacetylated into chitosan by three chitin deacetylases:
Cda1, Cda2, and Cda3 (9, 10).
Three C. neoformans strains have been engineered to be deﬁcient in chitosan
production, via gene deletions of CHS3, CSR2, or all three CDA genes. Chitosan in these
three strains was undetectable or very low by biochemical assay or using a chitosan-
speciﬁc stain (9, 10). The phenotypes of these strains demonstrated that chitosan is
important for (i) cell wall integrity, (ii) cell budding, (iii) cell size and morphology, and
(iv) virulence (8, 9). Previously we demonstrated that in a mouse inhalation model of
infection, chitosan-deﬁcient strains are avirulent and can be cleared within 2 days (8).
We examined the host immune response to infection with the cda1Δ cda2Δ cda3Δ
(cda123) chitosan-deﬁcient strain and found an increase in the Th1-mediated
immune response. Mice infected with this strain were also fully protected from subse-
quent challenge with wild-type KN99 (11). We, along with other groups, have shown
that these immunological responses are necessary for protection from subsequent C.
neoformans infections (12, 13). Taken together, these results identify chitosan as being
important for C. neoformans virulence.
Based on the rapid clearance of the cda1Δ cda2Δ cda3Δ chitosan-deﬁcient strain, we
hypothesize that compounds that interfere with chitosan biosynthesis and cause
chitosan deﬁciency could facilitate clearance of C. neoformans and that these com-
pounds would provide clues to additional pathways and proteins that regulate or contrib-
ute to chitosan production. Therefore, we developed a novel, medium-throughput, cell-
based, phenotypic ﬂow cytometry screening assay to identify small molecules that
reduce chitosan levels. We screened the Institute of Chemistry and Cell Biology (ICCB)
Known Bioactives library and discovered that the aminoalkylindole BML-190 targets the
C. neoformans G-protein-coupled receptor (GPCR) Gpr4 and, via the cyclic AMP (cAMP)/
protein kinase A (PKA) signaling pathway, contributes to an intracellular accumulation
of cAMP that results in decreased chitosan.
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RESULTS
A novel medium-throughput ﬂow cytometry assay that robustly measures
chitosan levels by BR ﬂuorescence. To identify small molecules that can inhibit
chitosan production, we developed a cell-based phenotypic medium-throughput ﬂow
cytometry screen that was identiﬁed as robust, meaning that it has high precision and
good dynamic range, based upon calculating the Z-prime, a calculation commonly
used to assess the quality of higher-throughput screening assays (14). Assays with
Z-primes greater than 0.5 are considered robust. The chitosan-selective ﬂuorescent dye
used for this assay was Cibacron brilliant red (BR) (see Fig. S1A in the supplemental
material). BR is an anionic dye that binds selectively to chitosan and has been used
previously in chitosan assays (15, 16). Staining occurs by an ionic bond forming
between the anionic dye and the protonated amino groups from chitosan.
We conﬁrmed that this ﬂow cytometry-based assay reliably detects differences in
chitosan contents of strains of Cryptococcus by comparing it to the low-throughput
3-methyl-2-benzothiazolone hydrazone hydrochloride (MBTH) chitosan assay (17, 18).
We found a statistically signiﬁcant positive correlation between the ﬂuorescence from
BR-stained C. neoformans strains that differentially produce chitosan, measured via ﬂow
cytometry, compared to the levels of chitosan in the same strains, as measured by the
MBTH assay (Fig. S1B and C). The key advantages of the ﬂow cytometry-based assay
over the MBTH assay are its miniaturized, microplate format (96 well), increased
throughput, and the ability to measure multiple parameters from a single sample/well.
Screening strategy to identify small-molecule inhibitors of chitosan synthesis
in C. neoformans. We chose to screen the 480 compound Institute of Chemistry and
Cell Biology (ICCB) Known Bioactives library because the biological targets of the
compounds in this library are known, allowing us to potentially identify the mechanism
of action of our hits. We developed a screening strategy funnel (Fig. S2) that uses a
series of assays that are increasingly sensitive in the ability to identify small-molecule
inhibitors of chitosan production so primary hits from the ﬂow cytometry assay could
be conﬁrmed by orthogonal approaches.
There are ﬁve proteins that are already known to affect chitosan production: Chs3,
Csr2, Cda1, Cda2, and Cda3 (8–10). Ideally, the screen would identify inhibitors of each
of these proteins, along with other, as yet unknown, proteins or pathways. However,
the Cdas are functionally redundant, making it less likely that the screen would identify
a deacetylase inhibitor. Therefore, we did our initial screening with a strain that
expressed only the CDA1 gene. We chose CDA1 because it is upregulated in the mouse
upon infection and deletion of CDA1 results in avirulence, while deletion of both CDA2
and CDA3 maintains virulence similar to that of the wild type (18). Therefore, for
screening, we chose a strain that expresses CDA1 but has both CDA2 and CDA3 deleted
(i.e., cda23). The cda23 strain produces sufﬁcient chitosan (Fig. S1), retains a
wild-type morphology for our screens, and has all the remaining elements of the
chitosan production machinery intact, so we should still have been able to identify
inhibitors of other factors that impact chitosan production from our screens. The
negative control for this screen was the untreated cda23 strain, and the positive
control was the chitosan-deﬁcient cda123 strain.
To minimize concerns associated with the viability of screening strains, prior to
subjecting them to the primary screening conditions, they were grown in the optimal
growth liquid medium yeast extract-peptone-dextrose (YPD) for 3 days at 30°C under
constant shaking (300 rpm). Next, they were washed twice in phosphate-buffered saline
(PBS) and then added at 5 105 cells/ml to 96-well round-bottom plates containing
100 l of complete RPMI medium (cRPMI) (0.625% heat-inactivated fetal bovine serum
[HI-FBS]) and 1 l of the ICCB library compound for a 1% dimethyl sulfoxide (DMSO)
ﬁnal concentration with varied compound concentrations (i.e., 1 M, 10 M, 5 g/ml,
or 50 g/ml). The varied compound concentrations were based upon what was pro-
vided by the supplier. Furthermore, the ICCB library compounds were screened in
duplicate to help reduce the likelihood of false negatives. In the context of growth
conditions considered, if compounds do have an effect on altering chitosan levels, for
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them to even have the potential for preclinical to clinical applications, they would
ultimately need to do so under host conditions. Therefore, we chose to characterize
their effects under conditions that would most closely simulate those of a mammalian
host (i.e., complete RPMI, 5% CO2, and 37°C). After 3 days under tissue culture condi-
tions, cells were stained with BR and then ﬁxed in 1% paraformaldehyde (PFA) (Fig. 1A).
Plates were then analyzed for BR ﬂuorescence by ﬂow cytometry. Speciﬁcally, from
each well, 7,500 cell events were collected from a gated region, within the forward
scatter (FSC) versus side scatter (SSC) dot plots. Doublet cell events were not excluded
since this is a phenotype of our chitosan-deﬁcient cda123 strain. These populations
were then examined for BR ﬂuorescence. The amount of BR ﬂuorescence from the
screening strain within each well was calculated by determining the BR geometric
mean ﬂuorescence intensity (gMFI) from the samples using unstained cda23 strain
as a negative control to set the gMFI gate (Fig. 1B). The gMFI was then used to calculate
BR fold ﬂuorescence by dividing those numbers by the gMFI of our unstained cda23
sample on each plate thereby quantiﬁng the relative levels of chitosan production
upon exposure of C. neoformans strains to different compounds (Fig. 1C). This medium-
throughput screen (12 plates) was completed in 6 h and had an average plate
Z-prime of 0.51, providing us conﬁdence that we have an efﬁcient and robust assay
(14).
We identiﬁed initial hits based upon the following criteria: the compound must
induce the cda23 strain to have a BR fold ﬂuorescence that is (i) statistically different
and (ii) at least 2-fold lower in signal than the untreated cda23Δ screening strain
(Fig. 1C). This resulted in the identiﬁcation of eight hits from the ICCB library (Table 1).
Based upon the stringency of our hit criteria, this equated to a hit rate of 1.7%, which
FIG 1 Primary screening strategy. (A) An overview of the primary cell-based phenotypic screen of the 480 compounds from the ICCB
library. (B) From each well, 7,500 cell events were collected and further analyzed for geometric mean ﬂuorescence intensity (gMFI) BR
ﬂuorescence. (C) Upon comparison to controls, BML-190 was identiﬁed as a tentative hit. Cibacron BR fold ﬂuorescence  gMFI of
BR-stained cda2Δ3Δ strain with drug/gMFI of unstained cda23 strain. Means were compared to that of the positive control using a
one-way ANOVA followed by the Bonferroni multiple-comparison test. A t test was used to show a difference between our screening strain
with and without drug. ns, not signiﬁcant.
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is below what is commonly seen for the screening of the ICCB library (i.e., 2% to 15%
[19–23]).
One effect that the initial hit compounds could have on screening strains is causing
their relatively reduced growth or cell death of the cda23 strain, unrelated to
chitosan deﬁciency. We anticipated that compounds that recapitulate the phenotype of
our chitosan-deﬁcient cda123 strain might have similar, modest growth defects
but that the strains should grow as well as or better than the cda123 strain.
Compounds that inhibited the growth more than for the cda123 strain likely act
through a different mechanism than chitosan deﬁciency and were eliminated. We also
repeated the assay used for the primary screen to generate a dose-response proﬁle for
each hit. However, two of the eight compounds, grayanotoxin III and RK-682, were
eliminated from this analysis due to their high costs compared to those of the other six
hits; these two compounds will be assessed further in the future. Hits were assessed for
causing growth inhibition on cda23 or wild-type cells by using ﬂow cytometry to
measure the difference in their concentration over 3 days of growth in cRPMI and under
tissue culture conditions. Dose response and proliferation validations were done as
described above. We validated 2 of the 6 remaining hits (Table 1), BML-190 (Fig. 2) and
dipyridamole (Fig. S3).
The aminoalkylindole BML-190 reduces chitosan synthesis in C. neoformans.
Our secondary screen used the MBTH biochemical assay to measure chitosan. There-
fore, we conﬁrmed the role of BML-190 and dipyridamole in recapitulating the phe-
notype of our chitosan-deﬁcient strain (i.e., reducing chitosan levels and growth of
wild-type C. neoformans, albeit not signiﬁcantly less than our chitosan-deﬁcient strain)
by our secondary screen using the biochemical assay to measure chitosan production
rather than the ﬂuorescence detection method that we used for our primary and
validating screens (Fig. 2B to D and Fig. S3B to D) and eliminated the four other
compounds. BML-190 is known as an inverse agonist of G-protein-coupled receptors
(GPCRs) (24). To our knowledge, there was no known connection between GPCRs and
chitosan production in C. neoformans; thus, we chose to further characterize the effect
of BML-190 in C. neoformans and to explore the potential role of GPCR signaling in the
synthesis of chitosan.
BML-190 reduces chitosan production in multiple research and clinical strains
of C. neoformans. C. neoformans var. grubii (serotype A) strains are important contrib-
utors to cryptococcosis in humans (25). Two congenic mating strains from this group,
KN99 and KN99a, along with clinical strains TDY1989 and TDY2001 were treated with
10 M BML-190, and all demonstrated a reduction in chitosan production (Fig. 3).
However, as expected, no chitosan was detectable with Saccharomyces cerevisiae or our
cda123 strain, which are both chitosan deﬁcient. This helps further support the
speciﬁcity of BR for measuring chitosan since S. cerevisiae is known to produce chitosan
only during sporulation (26) and we have empirically shown chitosan deﬁciency with
our cda123 strain.
BML-190 acts through the G-protein-coupled receptor Gpr4 of C. neoformans.
In human cells, BML-190 targets the GPCR cannabinoid receptors 1 and 2 (CNR1/2), with
a greater afﬁnity toward CNR2 (24). GPCRs are a family of receptors that are known to
be activated by external molecules that are well known to induce signal transduction
TABLE 1 Primary screen ICCB Known Bioactives library hits
Name Classiﬁcation Known mode of action
BML-190 Bioactive lipid Cannabinoid CB1/CB2 inverse agonist
DL-PDMP Lipid biosynthesis Glucosylceramide synthase inhibitor
Quercetin Kinase inhibitor Kinase inhibitor
Dipyridamole Inhibitor cGMP phosphodiesterase inhibitor
HA1077 Kinase inhibitor Inhibitor of Rho-dependent kinases
Juglone Inhibitor PIN1 inhibitor
Grayanotoxin III Ion channel ligand Sodium channels
RK-682 Inhibitor VHR phosphatase inhibitor
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in the cAMP pathway, which is important for many cellular responses. BML-190 acts as
an inverse agonist of this receptor, resulting in increased cAMP levels (24). Since
G-protein signaling is known to be conserved among organisms, with particular
importance associated with fungal virulence (27, 28), we examined if BML-190’s mode
FIG 2 The cannabinoid inverse-agonist BML-190 decreases chitosan levels. (A) Chemical structure of BML-190 (indo-
methacin morpholinylamide), an aminoalkylindole. (B) C. neoformans concentrations determined by ﬂow cytometry using
counting beads with BML-190 concentrations of 0 to 20 M. (C) Effect of BML-190 on the chitosan levels of wild-type C.
neoformans as measured by BR. BR fold ﬂuorescence  gMFI of BR-stained KN99 with BML-190/gMFI of unstained
KN99 (n 3). (D) Effects of various doses of BML-190 on the chitosan content as measured by the MBTH assay (n 3).
Means among groups were compared to those for the cda1Δ2Δ3Δ strain (B) or KN99 (C and D) with no BML-190 added
using a one-way ANOVA followed by the Bonferroni multiple-comparison test.
FIG 3 BML-190 causes chitosan reduction in multiple strains. C. neoformans strains were cultured with and without
BML-190 (10 M) for 3 days, stained with BR, and measured for BR fold ﬂuorescence by ﬂow cytometry (n 3). A
Student t test was used to show a difference between strains with and without drug.
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of action could also target GPCRs from C. neoformans (29). Initially, we looked for the
closest homologs to CNR1/2 in C. neoformans using BLAST and multiple-sequence
alignments. We identiﬁed four, GPR2, GPR3, GPR4, and GPR5, although none have more
than 30% similarity to the human CNR1/2. To identify the target of BML-190, we used
strains that had deletions of each of the four GPCRs. These deletion strains were
available from the Madhani UCSF C. neoformans knockout collection obtained from the
Fungal Genetics Stock Center (FGSC) (30, 31). After culturing these strains with BML-190
in cRPMI for 3 days under tissue culture conditions, we discovered that of these four,
only the gpr4 strain showed no decrease in chitosan in response to BML-190 (Fig. 4A
and Fig. S4). Because the gpr4 strain was nonresponsive to BML-190, Gpr4 may be the
primary receptor for BML-190 in C. neoformans.
Agonists of cannabinoid receptors are known to contribute to the degradation of
intracellular cAMP (32, 33). Similarly, in C. neoformans, Gpr4 activates the cAMP/PKA
pathway upon stimulation by the agonists glucose and the amino acid methionine,
which ultimately results in cAMP degradation (29, 34). Inversely, if BML-190 targets
Gpr4, and acts as an inverse agonist, then it should cause a buildup of cAMP in
wild-type cells but not in the gpr4 strain. Therefore, we determined the intracellular
content of cAMP in wild-type C. neoformans and the gpr4 strain with and without
10 M BML-190. We incubated strains with and without BML-190 for 30 min, processed
FIG 4 The G-protein-coupled receptor Gpr4 is necessary for BML-190 to reduce chitosan levels. (A) The C.
neoformans gpr-deﬁcient strains were cultured with and without BML-190 (10 M and 20 M) for 3 days, stained
with BR, and measured for gMFI by ﬂow cytometry (n 4). (B) BML-190 induces intracellular accumulation of cAMP
in wild-type C. neoformans but not in a gpr4Δ strain. Means among groups were compared to those of strains with
no BML-190 added using a one-way ANOVA followed by the Bonferroni multiple-comparison test or a Student t
test.
cAMP Regulates Chitosan Production in Cryptococcus ®
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cells to stably collect cAMP, and demonstrated that BML-190 causes an increase in
intracellular cAMP from wild-type cells but not the gpr4 strain (Fig. 4B). Based on these
results, we hypothesize that BML-190 targets Gpr4 and causes an increase in C.
neoformans intracellular cAMP that inversely correlates with a decrease in chitosan.
BML-190 reduces chitosan by increasing cAMP levels via the cAMP/PKA path-
way. Gpr4 is known to be a receptor in C. neoformans for the cAMP/PKA pathway (29).
Therefore, we hypothesized that BML-190 increases cAMP in wild-type Cryptococcus by
acting as an inverse agonist to the cAMP/PKA pathway, which is responsible for
regulating cAMP. To test that idea, we selected three additional strains with deletions
of genes in this pathway, including deletions of GPA1, CAC1, and PKA1. Gpa1 is the
G-protein alpha subunit of the heterotrimeric G-protein complex that interacts with
Gpr4. Upon ligand activation, Gpr4 activates Gpa1 and dissociates it from the complex
to continue the signal transduction cascade binding to the adenylyl cyclase (Cac1),
which converts ATP to cAMP. Based upon our hypothesis that cAMP levels are inverse
to chitosan, the deletion of either GPA1 or CAC1 is predicted to decrease cAMP
production and increase chitosan. Following the incubation of these different strains for
3 days in cRPMI under tissue culture conditions, the gpa1 and cac1 strains both
showed an increase in chitosan production compared to that of the wild type, and
increasing doses of BML-190 had no effect on chitosan in these deletion strains (Fig. 5).
We also conﬁrmed that addition of BML-190 to the cac1 strain does not affect chitosan
levels, as measured by the MBTH biochemical assay (data not shown). Photomicro-
graphs of BR-stained wild-type (KN99) and mutant strains with and without 10 M
BML-190 further conﬁrmed the results of our ﬂow cytometry analysis (Fig. 6).
Pka1 is the catalytic subunit of protein kinase A, which is activated by the action of
cAMP on the regulator subunit Pkr1. Similar to the case with the upstream components
of the pathway, the pka1 strain showed an increase in chitosan, and BML-190 had no
effect on chitosan in this strain (Fig. 5), suggesting that Pka1 may be a negative
regulator of chitosan production.
Furthermore, through an examination of the other group of G proteins in this
signaling pathway, induced by BML-190, chitosan reduction is dependent on the
G-protein alpha subunit (Gpa) 1 but not subunit 2 or 3 (Fig. S5). Overall, these results
support the idea that BML-190 works through the cAMP/PKA pathway to positively
regulate cAMP and to negatively regulate chitosan production.
If cAMP is important in this pathway for regulating chitosan, we should be able to
recapitulate the effects of BML-190 with the addition of cAMP to wild-type C. neofor-
FIG 5 The mode of action for BML-190 to cause chitosan reduction is via the cAMP/PKA pathway. C.
neoformans strains deﬁcient in genes from the cAMP/PKA pathway were cultured with and without
BML-190 for 3 days in cRPMI (0.625% HI-FBS) at 37°C and 5% CO2. These strains were stained with BR and
measured for gMFI by ﬂow cytometry. BR fold ﬂuorescence  gMFI of BR-stained strain with BML-190/
gMFI of unstained KN99 (n 3). Means among groups were compared to those of strains with no
BML-190 added using either a Student t test or a one-way ANOVA followed by the Bonferroni multiple-
comparison test, where applicable.
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mans. When wild-type cells were incubated with increasing amounts of cAMP for 3 days
in cRPMI, under tissue culture conditions, we observed decreasing amounts of chitosan
(Fig. 7). This ﬁnding is consistent with the hypothesis that BML-190 causes an intracel-
lular accumulation of cAMP resulting in decreased chitosan. We tested this by adding
increasing concentrations of cAMP to cAMP/PKA pathway mutants to see if increasing
cAMP would reduce chitosan. We saw a modest, but statistically signiﬁcant, decrease in
chitosan in the wild type and the gpa1Δ and cac1Δ strains at 5 mM dibutyryl-cAMP
(Fig. 8). We also saw a smaller, albeit signiﬁcant, difference in the pka1Δ and gpr4Δ
strains.
The levels of BR ﬂuorescence were higher in the gpa1Δ and cac1Δ strains, suggest-
ing that the intracellular cAMP levels were lower in these strains than in the wild type
or the gpr4Δ strain. These data suggest that Cac1 and Gpa1 directly affect cAMP levels.
FIG 6 Photomicrographs showing BR ﬂuorescence on some cAMP/PKA pathway mutants with and without BML-190. C.
neoformans strains deﬁcient in genes from the cAMP/PKA pathway were cultured with and without 10 M BML-190 for 3 days
in cRPMI (0.625% HI-FBS) at 37°C and 5% CO2. These strains were stained with BR and examined by epiﬂuorescence using ﬁlter
sets for TRITC (excitation, 521 to 565 nm; emission, 553 to 633 nm).
FIG 7 cAMP addition to C. neoformans results in a negative regulation of chitosan. C. neoformans
wild-type cells were cultured with increasing concentrations of dibutyryl-cAMP for 3 days, stained with
BR, and measured for BR fold ﬂuorescence by ﬂow cytometry. Means among groups (n 5) were
compared to those of strains with no cAMP added using a one-way ANOVA followed by the Bonferroni
multiple-comparison test.
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Interestingly, the loss of Gpr4 does not appear to strongly decrease cAMP levels, based
on the level of BR ﬂuorescence. It is possible that loss of Gpr4 triggers compensating
changes that allow the cAMP/PKA pathway to maintain normal levels of cAMP. Fur-
thermore, since the pka1Δ strain is associated with a higher level of chitosan that is
attenuated with the addition of cAMP, this implies that the regulation of chitosan is
likely to be downstream of Pka1.
Finally, the role of cAMP in regulating chitosan can also be assessed by the addition
of a potential agonist, which should ultimately cause a decrease in cAMP and an
associated increase in chitosan. From the primary screen of the ICCB library, we found
an increase in BR ﬂuorescence associated with WIN 55,212-2, a known agonist of the
cannabinoid receptors CNR1 and CNR2 that causes decreased cAMP in mammalian cells
(32, 33). As predicted, incubation of WIN 55,212-2 compounds with wild-type C.
neoformans resulted in decreased intracellular cAMP and increased chitosan as mea-
sured by BR ﬂuorescence (Fig. 9). Next, we wanted to ascertain if the decrease in
intracellular cAMP caused by WIN 55,212-2 was due to the cAMP/PKA pathway. We
found that a dose-response of WIN 55,212-2 with the cAMP/PKA pathway mutant
strains resulted in an increase of chitosan in the wild type and gpr4 strain, a decrease
of chitosan from gpa1 strains, but no effect on the cac1 or pka1 strain (Fig. 10). This
suggests that WIN 55,212-2, similar to BML-190, works through the cAMP/PKA pathway
to regulate chitosan, but it does not use Gpr4 as a receptor to induce its effects. Also,
interestingly, it induces an inverse agonist effect when Gpa1 is not expressed, suggest-
ing that the core cAMP-producing proteins can be activated by multiple signals.
BML-190 has physiochemical properties that could enable clinical success. The
rule of ﬁve shows that 90% of orally administered drugs that have gone beyond phase
II clinical studies have the following physiochemical properties (35): (i) having a
molecular weight of500, (ii) having a water partition coefﬁcient (logP), predicted by
XlogP3, of5, (iii) being a hydrogen bond donor and acceptor of5 and10, respec-
tively, and (iv) having a rotatable-bond count of10. Furthermore, in consideration
that fatality associated with cryptococcosis is primarily found to occur due to dissem-
ination into the central nervous system (CNS), drugs that can gain entrance into this
location are ideal (36). Criteria identiﬁed for this to happen are drug compounds having
a polar surface area (PSA) of70 Å2, which will allow them to pass through the
blood-brain barrier. Based upon these physical criteria, BML-190 could be a potential
FIG 8 cAMP addition to C. neoformans cAMP/PKA pathway mutants rescues the ability of the pathway to reduce
chitosan. C. neoformans cAMP/PKA pathway mutants were cultured with increasing concentrations of dibutyryl-
cAMP for 3 days in cRPMI, stained with BR, and measured for BR fold ﬂuorescence by ﬂow cytometry. Means among
groups (n 3) were compared to those of strains with no cAMP added using a one-way ANOVA followed by the
Bonferroni multiple-comparison test.
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clinically successful drug (Fig. S6A); however, its potency is not high. Finally, cytotoxicity
(CC50) of BML-190 to human hepatoma cells measured by a 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay was not
found within the range tested (0.2 M to 100 M), suggesting minimal toxicity to
humans (Fig. S6B). However, BML-190 also binds to the cannabinoid receptors, sug-
gesting that it would not be without side effects. Together these results indicate that
it would have to go through much more optimization before being pursued as a
potential drug.
Overall, our results show that cAMP from the cAMP/PKA pathway is important for
chitosan regulation. The pathway can be induced by BML-190 acting through the
G-protein-coupled receptor Gpr4 (Fig. 11). The induction by BML-190 within this
pathway also requires Gpa1, Cac1, and Pka1.
DISCUSSION
C. neoformans causes life-threatening meningoencephalitis in persons with AIDS.
Even with antifungal therapy, mortality hovers around 30%. The current array of
FIG 9 The cannabinoid receptor agonist WIN 55,212-2 causes a decrease in cAMP and subsequent increase in chitosan. (A) Wild-type
C. neoformans (KN99) was cultured for 30 min in cRPMI with either 10 M BML-190 or WIN 55,212-2 and then collected and lysed
for intracellular cAMP competition ELISA (n 5). (B) A dose-response of WIN 55,212-2-cultured C. neoformans (KN99) incubated for
3 days in cRPMI, stained with BR, and measured for BR fold ﬂuorescence by ﬂow cytometry. Means among groups (n 3) were
compared to those of strains with no drug added using a one-way ANOVA followed by the Bonferroni multiple-comparison test.
FIG 10 WIN 55,212-2 regulates chitosan through the cAMP/PKA pathway. C. neoformans strains deﬁcient
in genes from the cAMP/PKA pathway were cultured with and without WIN 55,212-2 for 3 days, stained
with BR, and measured for gMFI by ﬂow cytometry. Means among groups (n 3) were compared to
those of strains with no drug added using a one-way ANOVA followed by the Bonferroni multiple-
comparison test.
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antifungals is insufﬁcient to reduce worldwide fungal disease due to inadequate
efﬁcacy caused by inherent toxicities and/or emerging drug resistance. These limita-
tions are, in part, due to a paucity of antifungal targets. Therefore, strategies that
involve the identiﬁcation of novel targets that could lead to therapies with increased
efﬁcacy are needed. One approach to fulﬁll this goal is the targeting of factors required
for growth in the host, such as chitosan production in C. neoformans. There is some
evidence to suggest that drugs targeting virulence factors may reduce the likelihood of
the development of antimicrobial resistance. The argument has been made that in the
context of natural selection, if a drug does not directly kill the microbe, such as the case
when targeting virulence factors, selective pressures are reduced and that the likeli-
hood of the drug selecting for tolerant variants of the target pathogen, and promoting
antimicrobial resistance in a population, may also be reduced (37–39). Furthermore,
because chitosan deﬁciency inhibits C. neoformans survival in mammalian hosts (8, 11),
even in immunocompromised hosts (data not shown), and chitosan is not produced by
mammals, chitosan biosynthesis may be an ideal novel drug target for the treatment of
cryptococcosis, in particular, in the context of AIDS patients who are CD4 T cell
deﬁcient.
Through our development of a novel and robust ﬂow cytometry primary screen for
compounds that reduce chitosan production, we identiﬁed a compound, BML-190, that
reduces chitosan. BML-190 is an inverse agonist targeting the G-protein-coupled
human cannabinoid receptors CNR1 and CNR2. It induces adenylyl cyclase activity and
causes an intracellular accumulation of cAMP (24). Since G-protein signaling is known
to be conserved among organisms, and the cAMP/PKA signaling pathway that regu-
lates cAMP is known within C. neoformans, we explored the importance of a receptor
for this pathway, Gpr4, as a target for BML-190. We treated known GPCR gene deletions,
gpr3 (Fig. S4), gpr2, gpr4, and gpr5, with BML-190 and showed that in all but the
gpr4 strain, BML-190 was able to cause a reduction of chitosan (Fig. 4A).
We found increased cAMP levels in wild-type cells treated with BML-190 but not in
gpr4 cells (Fig. 4B). We further tested our hypothesis that cAMP levels governed by the
FIG 11 A proposed model for the target and the mode of action of BML-190 in C. neoformans. cAMP
from the cAMP/PKA pathway is important for chitosan regulation. The pathway can be induced by
BML-190 acting through the G-protein-coupled receptor Gpr4. By analogy of BML-190 in the mammalian
system, it is likely that it binds to Gpr4. The induction by BML-190 within this pathway also requires Gpa1,
Cac1, and Pka1. Not shown are the potential interactions and cross talk with other signaling pathways,
such as the cell integrity/PKC1/MPK1 pathway (44). Pathway illustration adapted from the work of
Kronstad et al. (28).
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cAMP/PKA pathway regulate chitosan levels by the use of another small molecule
identiﬁed in our screen. We showed a decrease in cAMP and an increase in chitosan in
cells when we treated cells with WIN 55,212-2, an agonist toward CNR1 and CNR2 (33),
supporting the involvement of the cAMP/PKA pathway (Fig. 8). Furthermore, another
conﬁrmed hit from our screen, dipyridamole, is a known phosphodiesterase inhibitor
that facilitates the intracellular accumulation of cAMP by preventing its hydrolysis into
inactive AMP (40, 41). This compound also shows a dose-dependent reduction in
chitosan (Fig. S3). Our work has not directly shown that BML-190 or WIN 55,212-2 binds
to Gpr4, or the speciﬁc mechanism of action of these two compounds, and further
experimentation is needed to conclusively determine binding. However, by analogy to
the mammalian system and the binding of these two compounds to CNR1 and CNR2,
along with our data showing nonresponse to these compounds in a gpr4 strain,
Occam’s razor (the law of parsimony) would predict that Gpr4 is their target.
C. neoformans PKA is a tetrameric protein that is made up of a dimeric regulatory
subunit (Pkr1) and two monomeric catalytic subunits (Pka1/2). Upon cAMP targeting of
Pkr1, PKA becomes activated and releases Pka1/2, which activates downstream targets
by phosphorylation. It has been noted that most of the physiological effects from cAMP
in fungi are mediated through targeting PKA (42, 43). To provide intracellular cAMP for
PKA targeting, Gpr4 acts as a receptor for glucose and methionine to trigger signaling
through the cAMP/PKA pathway (29). When Gpr4 is physically associated with Gpa1,
the adenylyl cyclase enzyme (Cac1) is activated to convert ATP into cAMP.
One important effect of PKA, through this pathway, is that it has been noted to
regulate C. neoformans virulence. Speciﬁcally, pka1, gpa1, and cac1 mutant strains
have reduced virulence along with reduced melanin and capsule volume (28, 43, 44).
Furthermore, PKA is known to promote cell proliferation and negatively regulates
cAMP, acting as a negative-feedback loop for PKA activity via its activation of phos-
phodiesterase (Pde1 [34]). Since we showed that chitosan production is inversely
related to cAMP levels (Fig. 2C and D and Fig. 8) and that there is no decrease in
chitosan in the pka1, gpa1, and cac1mutant strains with increasing concentrations
of BML-190 (Fig. 5), it can be further supported that the mode of action of BML-190 is
the cAMP/PKA pathway. Interestingly, the chitosan levels are higher in these mutant
strains than in the wild type with/without BML-190. Since we have noted that there is
an inverse relationship between chitosan and cAMP production, lower cAMP should
produce greater chitosan. This would be the case in gpa1 and cac1 mutants since
the corresponding proteins are noted to be important for cAMP formation. However,
this does not explain the higher chitosan production in pka1 mutants, which should
have relatively large amounts of cAMP (34) because Pde1 is not activated by Pka1 to
degrade cAMP. One possibility is that cAMP is negatively regulated by mechanisms in
addition to Pde1. Also, through our dose-response of adding exogenous cAMP to
pka1, in turn, causing a loss of chitosan (Fig. 8), it suggests that cAMP levels are indeed
low in the examined cAMP/PKA deletion strains, which conforms to our hypothesis of
the inverse relationship between cAMP and chitosan. It is possible that pka1 mutants
grown under optimal growth conditions (i.e., YPD growth conditions) show greater
cAMP levels than those grown under host conditions (i.e., cRPMI growth at 37°C and 5%
CO2), the latter of which were used for this study.
As previously stated, PKA is a well-described mediator of the effects of cAMP on
inducing virulence factors in C. neoformans. This has been identiﬁed to include the
organism’s ability to proliferate under host conditions (37°C) and to produce an
antiphagocytic polysaccharide capsule and antioxidant melanin (28, 43) and now
chitosan as well. Surprisingly, not only does BML-190 reduce chitosan, but also our data
suggest that it reduces capsule volume and melanin (Fig. S7 and S8). Based upon our
evidence that BML-190’s mode of action is the cAMP/PKA pathway, with cAMP target-
ing PKA to induce a mechanism downstream to cause a reduction in chitosan, it is also
possible that this downstream mechanism is responsible for causing a reduction in the
other virulence factors of capsule volume and melanin as well as decreased growth at
37°C (Fig. 2). Future studies will also examine the effects of BML-190 on Crg2 since it has
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been identiﬁed to be important in the cAMP/PKA pathway in negatively regulating
cAMP, in turn facilitating C. neoformans virulence (45). Another possibility is that cross
talk occurs between another pathway involved in regulating virulence factors such as
the cell wall integrity (CWI) pathway, which we have shown interacts with the cAMP/
PKA pathway (46). However, this mechanism has yet to be elucidated.
In conclusion, the paucity of drug targets and the lower efﬁcacy of current treat-
ments for cryptococcosis, a prominent cause of morbidity and mortality in AIDS
patients, mean that additional treatments must be discovered. To help increase efﬁ-
cacy, drugs and their targets must be found that target the pathogen and are nontoxic
to the host. By targeting chitosan of the pathogen, we provide a strategy that fulﬁlls
those criteria. However, because BML-190 also has been shown to have effects on
cannabinoid receptors, it is unlikely to be developed further as an anticryptococcus
drug, but additional screening for reduced chitosan using the ﬂow cytometry cell-based
screen could identify compounds that do not impact the mammalian host. Further-
more, by the drug disarming the pathogen, as opposed to killing it within the host, it
is possible that there may be a reduced effect of natural selection by the drug on the
pathogen and, in turn, a potential reduction in their antimicrobial resistance to the
drug, but this remains to be determined.
Our discovery that BML-190 negatively regulates chitosan via the cAMP/PKA signal-
ing pathway also suggests that our screening strategy can identify more compounds
from additional drug libraries that will regulate chitosan production from C. neoformans
to further identify key genes and proteins critical for the production and regulation of
chitosan and cell wall biosynthesis.
MATERIALS AND METHODS
Cryptococcus strains and growth conditions. C. neoformans strain KN99, the mCherry reporter
strain (KN99mCH [47]), and strains engineered that differentially express chitosan, i.e., cda1Δ, cda2Δ
cda3Δ, and cda1Δ cda2Δ cda3Δ strains (the last two referred to as cda23 and cda123 strains,
respectively, throughout this report), have been described previously (9). Additional strains used in-
cluded those derived from KN99 with single deletions in G-protein-coupled receptors, G-protein alpha
subunits, and the cAMP/PKA pathway that were part of the deletion library generated by Hiten Madhani
at the University of California, San Francisco (UCSF), and obtained from the Fungal Genetic Stock Center
(FGSC [30, 31]). These deletion strains (followed by gene identiﬁer [ID]) were gpr2Δ (CNAG_01855), gpr3
(CNAG_03846), gpr4 (CNAG_04730), gpr5 (CNAG_05586), gpa1 (CNAG_04505), gpa2 (CNAG_
00179), gpa3 (CNAG_02090), cac1 (CNAG_03202), and pka1 (CNAG_00396) strains. All strains were
streaked onto yeast-peptone-dextrose (YPD) agar plates from –80°C stocks. After the development of
colonies, strains were further propagated by their addition to YPD broth and grown for 72 h at 30°C and
300 rpm.
Flow cytometry cell-based phenotypic screening assay. We screened 480 compounds from the
Institute of Chemistry and Cell Biology (ICCB) Known Bioactives library (Enzo Life Sciences) using our
optimized cell-based ﬂow cytometry phenotypic assay. We used a Biomek FX workstation to add 1 l of
each compound to columns 2 to 11 of 96-well sterile round-bottom tissue culture plates in duplicate. For
the controls, 1 l of DMSO was added to columns 1 and 12. The screening strain (cda23) and the
chitosan-deﬁcient strain (cda123) were initially cultured in the complete growth medium YPD,
washed twice in 1 PBS, counted by hemocytometer, and resuspended at 5 105 cells/ml in complete
RPMI (cRPMI; 0.625% HI-FBS). We added 100 l of cells per well, for a ﬁnal DMSO concentration of 1%,
which ensured the solubility of the ICCB compounds. We found minimal impact on growth of either
strain under these conditions (data not shown). Plates were incubated for 3 days at 37°C with 5% CO2.
After incubation, we washed the cells with 1 PBS and stained them with Cibacron brilliant red 3B-A (BR)
for 20 min at a ﬁnal concentration of 5 g/ml in PBS, pH 2. We resuspended one well of the screening
strain in 1 PBS at pH 2 without BR as an unstained control to measure background ﬂuorescence. Cells
were then pelleted via centrifugation at 1,000 g for 10 min at room temperature in the plates, ﬂick
decanted, and ﬁxed by resuspension in 1% paraformaldehyde (PFA) followed by overnight incubation at
4°C. Prior to ﬂow cytometry we centrifuged the plates and ﬂick decanted and resuspended the cells in
ﬂow cytometry buffer (0.5% bovine serum albumin [BSA] plus 2 mM EDTA plus 1 PBS). All plates were
then analyzed for multiple parameters using a BD Biosciences LSRFortessa X-20 ﬂow cytometer equipped
with a high-throughput sampler (HTS), which enables automated sample acquisition from 96- and
384-well microtiter plates. BR ﬂuorescence was detected by excitation with a yellow-green laser (561 nm)
and emission collection with the PE channel (586/15 nm). We were able to complete the analysis of 12
plates (1,152 wells  compounds  controls) in 6.5 h. The average Z-prime for these 12 plates was 0.51,
indicative of a robust screening assay (14).
3-Methyl-2-benzothiazolone hydrazone hydrochloride (MBTH) chitosan assay. C. neoformans
strains were grown in 25 ml of cRPMI (0.625% HI-FBS) at 5 105 cells/ml under tissue culture conditions
for 72 h at 37°C and 5% CO2. Cells were then pelleted into preweighed 15-ml conical centrifuge tubes
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by centrifugation (3,000 g for 10 min). The supernatant was aspirated and then samples were
resuspended with 1 PBS and the cells were again pelleted. Pelleted cells were then weighed after being
freeze-dried to normalize chitosan measurements to dry weights. To reduce background chromogens,
cells were alkaline extracted by the addition of 10 ml of 6% KOH to cell pellets, followed by incubation
at 80°C for 90 min and periodic mixing. Pellets were then washed twice with 10 ml of 1 PBS followed
by two washes in ultrapure water. Samples were then all normalized to their initial dry weights by
addition of ultrapure water to make all samples 10 mg/ml.
For MBTH colorimetric determination of chitosan, samples of 100 l (1 mg) were diluted 1:1 with 1 M
HCl. Then 400 l of 0.36 M sodium nitrite was added, vortexed, and incubated for 15 min at room
temperature. Next 200 l of 1.1 M ammonium sulfamate was added, vortexed, and incubated for 5 min
at room temperature. This was then followed by the addition of 200 l of 0.011 M MBTH, followed by
vortexing and incubation for 30 min at 37°C. To induce blue color formation, 200 l of 0.018 M iron(III)
chloride hexahydrate was added and vortexed, followed by incubation for 5 min at 37°C. Samples were
cooled to room temperature and centrifuged at 14,000 rpm for 2 min. One hundred microliters of
supernatant from each sample was added to wells of a ﬂat-bottom 96-well microtiter plate and
absorbance was measured at 650 nm. A standard curve was prepared from 2-fold serial dilutions of 2 mM
GlcN for assessment of chitosan concentrations of samples.
cAMP measurements.We grew C. neoformans strains overnight in YPD, washed the cells twice in 1
PBS, and added them at a concentration of 5 108 cells/ml to T-175 tissue culture ﬂasks containing 10 ml
of cRPMI (0.625% HI-FBS) with a ﬁnal concentration of 1% DMSO with or without the testing compound.
We incubated the ﬂasks for 30 min at 37°C and 5% CO2 and then collected medium from each ﬂask and
centrifuged it at 3,000 g for 10 min at 4°C. We aspirated the media and resuspended the cell pellets
in 2 ml of ice-cold 0.1 M HCl, transferring 1.5 ml to 2-ml screw-top microtubes (Sarstedt Inc., Numbrecht,
Germany) on ice that contained 0.5-mm zirconia/silica beads (Biospec Products, Bartlesville, OK). Cells
were homogenized using a Mini-Beadbeater-16 (Biospec Products) at 75% of maximum agitation at 4°C
for 3 rounds of 2 min on and 2 min off. We transferred the homogenized samples to new tubes and
stored them at –20°C. We thawed the samples on ice, centrifuged them at 3,000 g for 10 min, and
transferred the supernatants to fresh tubes. We measured cAMP concentrations using a cAMP compet-
itive enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer’s instructions
(Sigma-Aldrich, St. Louis, MO). Samples were added to ELISA wells as 100-l aliquots (2.5 108 cell lysate
equivalent) and were not acetylated prior to measurements.
BR staining of C. neoformans for ﬂuorescence microscopy. We dissolved 10 mg/ml of BR in
ultrapure water. Cryptococcus cells grown in YPD were washed once in PBS (1,000 g for 10 min) and
diluted to 1 107/ml of PBS. Cells were then pelleted and resuspended in 5 g/ml of BR in PBS (pH 2),
followed by incubation at room temperature for 20 min in the dark. We washed the cells with 1 PBS
and resuspended them at 4 107/ml in PBS. We transferred 10 l to a microscope slide, covered it with
a coverslip, and sealed with nail polish. Slides were then examined by epiﬂuorescence using ﬁlter sets for
tetramethyl rhodamine isocyanate (TRITC) (excitation, 521 to 565 nm; emission, 553 to 633 nm).
Capsule measurements. Wild-type C. neoformans (KN99) cells were grown in cRPMI (0.625%
HI-FBS) and 0.1% DMSO with or without 20 M BML-190 for 3 days at 37°C and 5% CO2. Cells were then
washed in 1 PBS and resuspended in 1/4 dilution of India ink (50 l) and then added (10 l) to a
microscope slide. The diameters of the whole cell and cell body were measured from 60 different cells
within each biological replicate. Volume of a sphere was determined from those diameters. Capsule
volume was determined by subtracting the volume of the cell body from the volume of the whole cell.
Means between groups (n 3) were compared using a Student t test.
Melanin measurements. Wild-type C. neoformans (KN99) was grown in cRPMI (0.625% HI-FBS) and
0.1% DMSO with or without 20 M BML-190 for 3 days at 37°C and 5% CO2 (n 3). Cells were then
washed in 1 PBS. Then 1 108 cells (5 107/ml), from each condition described above, were added to
2 ml of glucose-free asparagine medium (1 g/liter of L-asparagine, 0.5 g/liter of MgSO4·7 H2O, 3 g/liter of
KH2PO4, and 1 mg/liter of thiamine, plus 1 mM L-3,4-dihydroxyphenylalanine [L-DOPA]) for 7 days at 300
rpm and 30°C. Samples were then spun down at 600 g for 10 min. Pellets were then transferred to
a 96-well ﬂat-bottom microtiter plate and photographed.
Statistical analysis. All data from experiments are from greater than or equal to three independent
experiments. Error bars represented standard deviations. Inferential statistics used at least one of the
following relevant parametric analyses: a two-tailed unpaired Student t test, a one-way analysis of
variance (ANOVA) with Bonferroni multiple-comparison test, and/or a Pearson’s r correlation analysis. For
all experiments, statistically signiﬁcant differences are indicated in ﬁgures as follows: *, P 0.05; **,
P 0.01; ***, P 0.001; and ****, P 0.0001. All statistical analysis was completed on Prism 7 for Mac OS
X software (version 7.0c).
Data availability. The screening data have been deposited in the publicly available PubChem
database under identifying number AID 1347148 (https://pubchem.ncbi.nlm.nih.gov/bioassay/1347148).
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